Research programme: GvHD therapeutics - GenmabAlternative Names: HuMab7D8
Latest Information Update: 10 Oct 2008
At a glance
- Originator Genmab
- Mechanism of Action CD20 antigen inhibitors; Complement activation stimulants; T lymphocyte inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Graft-versus-host disease
Most Recent Events
- 10 Oct 2008 Discontinued - Preclinical for Graft-versus-host disease in Netherlands (unspecified route)
- 19 Jan 2006 Preclinical trials in Graft-versus-host disease in Netherlands (unspecified route)